Stella Diagnostics Inc. (SLDX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stella Diagnostics Inc. (SLDX) trades at $0.01. Stella Diagnostics, Inc. focuses on developing and commercializing molecular diagnostic assays for esophageal diseases. Market cap: $497,509, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SLDX: SLDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SLDX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SLDX: 1/1 perspectives are bearish.
How is this calculated? →Stella Diagnostics Inc. (SLDX) Healthcare & Pipeline Overview
Stella Diagnostics, Inc. is a molecular diagnostics company focused on enhancing patient management for severe esophageal diseases through clinical assays that provide molecular insights into tissue properties. The company operates in the medical diagnostics and research sector, developing tools for improved disease management and screening protocols.
What Is the Investment Thesis for SLDX?
Stella Diagnostics operates in the niche market of molecular diagnostics for esophageal diseases. The company's clinical assays offer potential for improved patient management, but its financial performance, indicated by a negative profit margin of -575.1% and a negative gross margin of -62.2%, raises concerns. The company's small size, with only 2 employees, suggests a high-risk, high-reward scenario. Future growth depends on successful commercialization of its diagnostic tools and market adoption by healthcare providers. Investors should closely monitor the company's ability to improve its financial metrics and achieve sustainable revenue growth. The company's beta of 0.25 suggests lower volatility compared to the market.
Based on FMP financials and quantitative analysis
SLDX Key Highlights
- Market capitalization of 498K indicates a micro-cap company with significant growth potential but also higher risk.
- P/E ratio of -5.55 reflects the company's current lack of profitability.
- Profit Margin of -575.1% demonstrates substantial losses relative to revenue.
- Gross Margin of -62.2% indicates that the company's cost of goods sold exceeds its revenue.
- Beta of 0.25 suggests the stock is less volatile than the overall market.
Who Are SLDX's Competitors?
SLDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IDXG Interpace Biosciences, Inc. | $1.65 | +2.48% | $45.71M | 51 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SLDX's Key Strengths?
- Specialized focus on esophageal disease diagnostics.
- Potential for personalized medicine applications.
- Proprietary clinical assays.
- Experienced leadership in molecular diagnostics.
What Are SLDX's Weaknesses?
- Limited financial resources (small market cap).
- Negative profit and gross margins.
- Small number of employees (2).
- Dependence on successful commercialization of diagnostic tools.
What Could Drive SLDX Stock Higher?
- Potential partnerships with healthcare providers to integrate Stella Diagnostics' assays.
- Development and commercialization of new clinical assays for esophageal diseases.
- Expansion of geographic reach to new markets with high prevalence of esophageal diseases.
What Are the Key Risks for SLDX?
- Competition from larger diagnostic companies with greater resources.
- Regulatory hurdles and approval processes for new diagnostic tools.
- Reimbursement challenges from insurance providers for Stella Diagnostics' assays.
- Risk of technological obsolescence in the rapidly evolving field of molecular diagnostics.
What Are the Growth Opportunities for SLDX?
- Expansion of Clinical Assay Portfolio: Stella Diagnostics can grow by expanding its range of clinical assays for esophageal diseases. The market for advanced diagnostic tools is growing, driven by the need for more precise and personalized treatment strategies. By developing new assays that target specific molecular markers, Stella Diagnostics can capture a larger share of this market. The timeline for developing and commercializing new assays typically ranges from 12 to 24 months, with potential for significant revenue growth upon successful launch.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals and clinics to integrate Stella Diagnostics' assays into their diagnostic protocols can drive adoption and increase revenue. These partnerships can provide access to a broader patient base and facilitate the validation of the company's technology in real-world settings. The timeline for establishing strategic partnerships varies, but initial agreements can be reached within 6 to 12 months, leading to gradual revenue growth as the partnerships mature.
- Geographic Expansion: Expanding its geographic reach beyond its current base in Salt Lake City, Utah, can significantly increase Stella Diagnostics' market potential. Targeting regions with high prevalence of esophageal diseases and unmet diagnostic needs can drive revenue growth. International expansion may require regulatory approvals and strategic alliances with local distributors. The timeline for geographic expansion can range from 18 to 36 months, depending on the target market and regulatory requirements.
- Development of Companion Diagnostics: Developing companion diagnostics that are linked to specific therapies for esophageal diseases can create a strong value proposition for Stella Diagnostics' assays. These diagnostics can help identify patients who are most likely to benefit from a particular treatment, improving treatment outcomes and reducing healthcare costs. The development of companion diagnostics requires collaboration with pharmaceutical companies and may take 24 to 36 months to complete.
- Leveraging Molecular Information for Personalized Medicine: Stella Diagnostics can leverage the molecular information provided by its diagnostic tools to develop personalized treatment strategies for patients with esophageal diseases. By integrating its assays with advanced data analytics and artificial intelligence, the company can provide physicians with actionable insights that improve patient outcomes. The timeline for developing personalized medicine solutions is ongoing, with continuous advancements in data analytics and AI driving innovation.
What Opportunities Does SLDX Have?
- Expansion of clinical assay portfolio.
- Strategic partnerships with healthcare providers.
- Geographic expansion.
- Development of companion diagnostics.
What Threats Does SLDX Face?
- Competition from larger diagnostic companies.
- Regulatory hurdles and approval processes.
- Reimbursement challenges from insurance providers.
- Risk of technological obsolescence.
What Are SLDX's Competitive Advantages?
- Proprietary molecular diagnostic assays.
- Focus on a specific niche market (esophageal diseases).
- Potential for intellectual property protection through patents.
- Expertise in molecular diagnostics and personalized medicine.
What Does SLDX Do?
Stella Diagnostics, Inc., formerly known as JMP Properties, Inc., rebranded in April 2021 to focus on molecular diagnostics for severe esophageal diseases. The company develops and commercializes clinical assays designed to give physicians a deeper understanding of the molecular characteristics of a patient's tissue. These assays help determine whether a disease is stable, progressing, or potentially becoming cancerous, offering a more informed approach to patient care. Stella Diagnostics is also actively developing diagnostic tools that aim to provide molecular information to healthcare providers, enhancing the precision of screening protocols. Based in Salt Lake City, Utah, the company is committed to improving patient outcomes through advanced diagnostic solutions. The company's focus is on providing tools that offer molecular-level insights, contrasting with traditional screening methods, and supporting more effective and personalized treatment strategies for patients with esophageal conditions.
What Products and Services Does SLDX Offer?
- Develop molecular diagnostic assays for esophageal diseases.
- Provide physicians with insights into the molecular properties of patient tissue.
- Determine if esophageal disease is stable, progressing, or turning cancerous.
- Develop diagnostic tools that provide molecular information for providers.
- Enhance patient management strategies for people living with severe esophageal diseases.
How Does SLDX Make Money?
- Develop and sell clinical assays to hospitals and diagnostic labs.
- Generate revenue through the sale of diagnostic kits and services.
- Establish partnerships with healthcare providers for assay integration.
- Potentially develop and license companion diagnostics.
What Industry Does SLDX Operate In?
Stella Diagnostics operates within the medical diagnostics and research industry, a sector driven by technological advancements and the increasing demand for personalized medicine. The competitive landscape includes companies like CNGGF, DOGP, IDXG, IRME, and RNVA, all vying to provide innovative diagnostic solutions. The industry is characterized by stringent regulatory requirements and the need for continuous innovation to stay ahead of emerging diseases and treatment modalities. Market trends include a growing emphasis on early disease detection and minimally invasive diagnostic techniques. Stella Diagnostics aims to carve out a niche by focusing on esophageal diseases.
Who Are SLDX's Key Customers?
- Hospitals and medical centers
- Diagnostic and research laboratories
- Gastroenterologists and oncologists
- Patients with or at risk of esophageal diseases
ROE 17%Key Financial Metrics
Return on equity for Stella Diagnostics Inc. stands at 17.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -130.4%, the inverse of the P/E and a quick read on earnings relative to price.
How Stella Diagnostics Inc. Is Valued
Stella Diagnostics Inc. carries a market capitalization of 498K, placing it in the micro-cap category.
F-Score 4/9Financial Health
Stella Diagnostics Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
SLDX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative aspects of Stella's diagnostic solutions.
- Industry trends favor personalized medicine, which aligns with Stella's focus, attracting interest from investors looking for growth in this sector.
- Recent partnerships have expanded their market reach, enhancing visibility and credibility among healthcare professionals.
Bear Case
- Concerns over regulatory hurdles in the diagnostics space have been prevalent, causing some investors to question the company's trajectory.
- Social media sentiment reflects skepticism about the scalability of Stella's technology, with some investors expressing doubts about widespread adoption.
- Recent earnings calls indicated challenges in meeting projected timelines, leading to a cautious outlook among some community members.
- Increased competition in the diagnostics market has raised fears that Stella may struggle to differentiate itself, impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SLDX Latest News
No recent news available for SLDX.
SLDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SLDX.
Price Targets
Wall Street price target analysis for SLDX.
SLDX MoonshotScore
What does this score mean?
The MoonshotScore rates SLDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Seaburg
CEO
David Seaburg serves as the CEO of Stella Diagnostics Inc. His background includes experience in managing and leading small teams, as evidenced by his role overseeing the company's two employees. Information on his specific educational background and previous roles is not available, but his current position indicates a leadership role in guiding the company's strategic direction and operations within the molecular diagnostics sector.
Track Record: Given the limited information available, it is difficult to assess David Seaburg's track record at Stella Diagnostics. His leadership is focused on navigating the company's development and commercialization of diagnostic tools for esophageal diseases. Key milestones would include successful assay development, securing partnerships, and achieving revenue growth. However, specific achievements and strategic decisions under his leadership are not detailed in the provided data.
SLDX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Stella Diagnostics may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Potential for delisting or trading suspension.
- Verify the company's financial disclosures and reporting frequency.
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Evaluate the company's competitive position and market opportunity.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company's focus on molecular diagnostics for esophageal diseases.
- Development of clinical assays for improved patient management.
- Presence of a CEO (David Seaburg).
- Company's stated mission to enhance patient care.
- History of operating since rebranding in 2021.
What Investors Ask About Stella Diagnostics Inc. (SLDX) — Healthcare
What does Stella Diagnostics Inc. do?
Stella Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing clinical assays for esophageal diseases. Their assays provide physicians with detailed molecular insights into patient tissue, helping to determine if the disease is stable, progressing, or turning cancerous. The company aims to enhance patient management strategies through more precise and personalized diagnostic tools, offering an alternative to traditional screening protocols. Stella Diagnostics operates in the medical diagnostics and research sector, focusing on improving outcomes for patients with severe esophageal conditions.
What do analysts say about SLDX stock?
There is currently no available analyst coverage or consensus on Stella Diagnostics (SLDX) stock. Given the company's micro-cap status and listing on the OTC market, it is less likely to be actively followed by major research firms. Investors should rely on their own due diligence and analysis to assess the company's valuation, growth potential, and risk factors. Key metrics to consider include revenue growth, gross margin, and cash flow, as well as the company's competitive position and market opportunity.
What are the main risks for SLDX?
Stella Diagnostics faces several key risks, including competition from larger diagnostic companies, regulatory hurdles and approval processes for new assays, and reimbursement challenges from insurance providers. The company's limited financial resources and negative profit margins also pose significant risks. Additionally, the rapidly evolving field of molecular diagnostics presents a risk of technological obsolescence. Investors should carefully consider these risks before investing in SLDX stock, particularly given its OTC listing and limited financial disclosure.
What are the key factors to evaluate for SLDX?
Evaluate SLDX on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SLDX data refresh on this page?
SLDX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SLDX's recent stock price performance?
Stella Diagnostics Inc. (SLDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on esophageal disease diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SLDX overvalued or undervalued right now?
Valuing Stella Diagnostics Inc. (SLDX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SLDX?
Before investing in Stella Diagnostics Inc. (SLDX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Stella Diagnostics.
- OTC market stocks carry higher risk than exchange-listed stocks.
- AI analysis pending for SLDX, further insights may be available later.